1.16

4.92% -0.06

After Hours: 1.21 0.05 +4.31%

Aptose Biosciences Inc (APTO)

Overview News Price History Why APTO Down? Discussions Forecast Stock Split

Aptose Biosciences Inc stock is currently priced at $1.16, with a 24-hour trading volume of 47,081. It has seen a -4.92% decreased in the last 24 hours and a -23.18% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.23 pivot point. If it approaches the $1.13 support level, significant changes may occur.

Previous Close:

$1.22

Open:

$1.19

24h Volume:

47,081

Market Cap:

$18.23M

Revenue:

Net Income/Loss:

$-51.21M

P/E Ratio:

-0.1483

EPS:

-7.82

Net Cash Flow:

$-44.62M

1W Performance:

-8.66%

1M Performance:

-23.18%

6M Performance:

-55.04%

1Y Performance:

+141.67%

1D Range:

$1.15

$1.235

52W Range:

$0.36

$6.6001

Aptose Biosciences Inc Stock (APTO) Company Profile

Name

Aptose Biosciences Inc

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

Address

251 Consumers Road, Suite 1105, Toronto, ON

Employee

Twitter

Next Earnings Date

2024-05-06

Latest SEC Filings

APTO's Discussions on Twitter

Aptose Biosciences Inc Stock (APTO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-19-20	Initiated	Cantor Fitzgerald	Overweight
Sep-22-20	Initiated	Alliance Global Partners	Buy
Feb-20-20	Initiated	Maxim Group	Buy
Feb-06-20	Reiterated	H.C. Wainwright	Buy
Jan-09-20	Initiated	Piper Sandler	Overweight
Mar-01-19	Initiated	RBC Capital Mkts	Outperform
Nov-16-18	Initiated	B. Riley FBR	Buy
Dec-13-17	Reiterated	H.C. Wainwright	Buy
Oct-23-17	Resumed	ROTH Capital	Buy
Sep-07-17	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-08-17	Initiated	Rodman & Renshaw	Neutral

View All

Aptose Biosciences Inc Stock (APTO) Latest News

What Makes Aptose Biosciences (APTO) a New Buy Stock

Zacks Investment Research

Aptose Reports Results for the Fourth Quarter and Full Year 2023

GlobeNewswire Inc.

Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024

GlobeNewswire Inc.

Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why

Zacks Investment Research

Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option

GlobeNewswire Inc.

Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical

GlobeNewswire Inc.

Aptose Biosciences Inc Stock (APTO) Financials Data

Aptose Biosciences Inc (APTO) Net Income 2024

APTO net income (TTM) was -$51.21 million for the quarter ending December 31, 2023, a -22.44% decrease year-over-year.

Aptose Biosciences Inc (APTO) Cash Flow 2024

APTO recorded a free cash flow (TTM) of -$44.62 million for the quarter ending December 31, 2023, a -37.94% decrease year-over-year.

Aptose Biosciences Inc (APTO) Earnings per Share 2024

APTO earnings per share (TTM) was -$7.72 for the quarter ending December 31, 2023, a -14.54% decline year-over-year.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.